Influenza Incidence Rates per 10 000 Person-weeks by Vaccine Type and Relative Vaccine Effectiveness of Recombinant Influenza Vaccine Compared to Standard-Dose Inactivated Influenza Vaccine Among Adults Aged 18–64 Years, 2022–2023 Influenza Season, Modified Analytic Intention-to-Treat Population (n = 3927)
| Type of Infection . | SD IIV (n = 1964) . | RIV (n = 1963) . | rVE, %b (95% CI) . | ||
|---|---|---|---|---|---|
| No. (Column %)a . | IR per 10 000 Person-weeks (95% CI) . | No. (Column %) . | IR per 10 000 Person-weeks (95% CI) . | ||
| Any influenza virus infection | 28 | 0.9 (.6–1.3) | 20 | 0.7 (.4–1.0) | 29 (−26 to 60) |
| A/H3N2 | 14 (50.0) | 0.5 (.2–.7) | 11 (55.0) | 0.4 (.2–.6) | 22 (−73 to 64) |
| A/H1N1 | 12 (42.9) | 0.4 (.2–.7) | 9 (45.0) | 0.3 (.1–.5) | 25 (−78 to 68) |
| Type of Infection . | SD IIV (n = 1964) . | RIV (n = 1963) . | rVE, %b (95% CI) . | ||
|---|---|---|---|---|---|
| No. (Column %)a . | IR per 10 000 Person-weeks (95% CI) . | No. (Column %) . | IR per 10 000 Person-weeks (95% CI) . | ||
| Any influenza virus infection | 28 | 0.9 (.6–1.3) | 20 | 0.7 (.4–1.0) | 29 (−26 to 60) |
| A/H3N2 | 14 (50.0) | 0.5 (.2–.7) | 11 (55.0) | 0.4 (.2–.6) | 22 (−73 to 64) |
| A/H1N1 | 12 (42.9) | 0.4 (.2–.7) | 9 (45.0) | 0.3 (.1–.5) | 25 (−78 to 68) |
Abbreviations: CI, confidence interval; IR, incidence rate; RIV, recombinant influenza vaccine; rVE, relative vaccine effectiveness; SD IIV, standard-dose inactivated influenza vaccine.
aAmong SD IIV recipients, there was 1 infection with a B/Victoria lineage virus and 1 infection with an unsubtypable influenza A virus.
bThe rVE was calculated as (1 − hazard ratio comparing RIV vs SD IIV) × 100%. Hazard ratios were estimated with Cox proportional hazards regression models. Models examining any influenza virus infection as an outcome were adjusted for site and age group (18–49, 50–64 years). Models examining influenza A subtype outcomes did not adjust for site or age group.
Influenza Incidence Rates per 10 000 Person-weeks by Vaccine Type and Relative Vaccine Effectiveness of Recombinant Influenza Vaccine Compared to Standard-Dose Inactivated Influenza Vaccine Among Adults Aged 18–64 Years, 2022–2023 Influenza Season, Modified Analytic Intention-to-Treat Population (n = 3927)
| Type of Infection . | SD IIV (n = 1964) . | RIV (n = 1963) . | rVE, %b (95% CI) . | ||
|---|---|---|---|---|---|
| No. (Column %)a . | IR per 10 000 Person-weeks (95% CI) . | No. (Column %) . | IR per 10 000 Person-weeks (95% CI) . | ||
| Any influenza virus infection | 28 | 0.9 (.6–1.3) | 20 | 0.7 (.4–1.0) | 29 (−26 to 60) |
| A/H3N2 | 14 (50.0) | 0.5 (.2–.7) | 11 (55.0) | 0.4 (.2–.6) | 22 (−73 to 64) |
| A/H1N1 | 12 (42.9) | 0.4 (.2–.7) | 9 (45.0) | 0.3 (.1–.5) | 25 (−78 to 68) |
| Type of Infection . | SD IIV (n = 1964) . | RIV (n = 1963) . | rVE, %b (95% CI) . | ||
|---|---|---|---|---|---|
| No. (Column %)a . | IR per 10 000 Person-weeks (95% CI) . | No. (Column %) . | IR per 10 000 Person-weeks (95% CI) . | ||
| Any influenza virus infection | 28 | 0.9 (.6–1.3) | 20 | 0.7 (.4–1.0) | 29 (−26 to 60) |
| A/H3N2 | 14 (50.0) | 0.5 (.2–.7) | 11 (55.0) | 0.4 (.2–.6) | 22 (−73 to 64) |
| A/H1N1 | 12 (42.9) | 0.4 (.2–.7) | 9 (45.0) | 0.3 (.1–.5) | 25 (−78 to 68) |
Abbreviations: CI, confidence interval; IR, incidence rate; RIV, recombinant influenza vaccine; rVE, relative vaccine effectiveness; SD IIV, standard-dose inactivated influenza vaccine.
aAmong SD IIV recipients, there was 1 infection with a B/Victoria lineage virus and 1 infection with an unsubtypable influenza A virus.
bThe rVE was calculated as (1 − hazard ratio comparing RIV vs SD IIV) × 100%. Hazard ratios were estimated with Cox proportional hazards regression models. Models examining any influenza virus infection as an outcome were adjusted for site and age group (18–49, 50–64 years). Models examining influenza A subtype outcomes did not adjust for site or age group.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
